Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca 2+ channels

British Journal of Pharmacology

Volumn 143, Issue 8, 2004, Pages 1050-1057

  Furukawa, Taiji ^a   Miura, Reiko ^b   Honda, Mitsuyoshi ^a   Kamiya, Natsuko ^a   Mori, Yasuo ^c   Takeshita, Satoshi ^a   Isshiki, Takaaki ^a   Nukada, Toshihide ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c NATIONAL INSTITUTES OF NATURAL SCIENCES   (Japan)

Author keywords

Efonidipine; Electrophysiology; Mammalian cell line; Optical isomer; Selective blocker; T type Ca 2+ channel; Xenopus oocyte

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE;

ANIMAL CELL; ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; DRUG EFFECT; ISOMER; MEMBRANE CURRENT; MEMBRANE ELECTROPHYSIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOPUS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELL LINE; CRICETINAE; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; STEREOISOMERISM; XENOPUS;

EID: 11244309316     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705944     Document Type: Article

References (42)

1. ANDREASEN, D., JENSEN, B.L., HANSEN, P.B., KWON, T.H., NIELSEN, S. & SKOTT, O. (2000). The alpha(1G)-subunit of a voltage-dependent Ca(2+) channel is localized in rat distal nephron and collecting duct. Am. J. Physiol. Renal Physiol., 279, F997-1005.
2. CANNON, B., HERMANSSON, M., GYORKE, S., SOMERHARJU, P., VIRTANEN, J.A. & CHENG, K.H. (2003). Regulation of calcium channel activity by lipid domain formation in planar lipid bilayers. Biophys. J., 85, 933-942.
3. CRIBBS, L.L., GOMORA, J.C., DAUD, A.N., LEE, J.H. & PEREZ-REYES, E. (2000). Molecular cloning and functional expression of Ca(v)3.1c, a T-type calcium channel from human brain. FEBS Lett, 466, 54-58.
4. FUJITA, Y., MYNLIEFF, M., DIRKSEN, R.T., KIM, M.-S., NIIDOME, T., NAKAI, J., FRIEDRICH, T., IWABE, N., MIYATA, T., FURUICHI, T., FURUTAMA, D., MIKOSHIBA, K., MORI, Y. & BEAM, K.G. (1993). Primary structure and functional expression of the Ὼ-conotoxin-sensitive N-type calcium channel from rabbit brain. Neuron, 10, 585-598.
5. 2+ channels with G-protein a and bg subunits II. evidence for direct binding. J. Biol. Chem., 273, 17595-17603.
6. 2+ channels by amlodipine. Br. J. Phamacol., 121, 1136-1140.
7. FURUKAWA, T., YAMAKAWA, T., MIDERA, T., SAGAWA, T., MORI, Y. & NUKADA, T. (1999). Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther., 291, 464-473.
8. HAMILL, O.P., MARTY, E., NEHER, B., SAKMANN, B. & SIGWORTH, F.J. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch., 391, 85-100.
9. HARADA, K., NOMURA, M., NISHIKADO, A., UEHARA, K., NAKAYA, Y. & ITO, S. (2003). Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ. J., 67, 139-145.
10. HAYASHI, K., OZAWA, Y., FUJIWARA, K., WAKINO, S., KUMAGAI, H. & SARUTA, T. (2003). Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am. J. Nephrol., 23, 229-244.
11. 2+ channel block and inactivation: common molecular determinants. Trends Pharmacol. Sci., 19, 439-443.
12. HERMSMEYER, K., MISHRA, S., MIYAGAWA, K. & MINSHALL, R. (1997). Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists. Clin. Ther., 19 (Suppl A), 18-26.
13. HOCKERMAN, G.H., PETERSON, B.Z., JOHNSON, B.D. & CATTERALL, W.A. (1997). Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol., 37, 361-396.
14. HULLIN, R., SINGER-LAHAT, D., FREICHEL, M., BIEL, M., DASCAL, N., HOFMANN, F. & FLOCKERZI, V. (1992). Calcium channel beta subunit heterogeneity: functional expression of cloned cDNA from heart, aorta and brain. EMBO J., 11, 885-890.
15. KRAYENBUHL, J.C, VOZEH, S., KONDO-OESTREICHER, M. & DAYER, P. (1999). Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol., 55, 559-565.
16. LEE, J.H., DAUD, A.N., CRISES, L.L., LACERDA, A.E., PEREVERZEV, A., KLOCKNER, U., SCHNEIDER, T. & PEREZ-REYES, E. (1999). Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family. J. Neurosci., 19, 1912-1921.
17. MARKSTEINER, R., SCHURR, P., BERJUKOW, S., MARGREITER, E., PEREZ-REYES, E. & HERING, S. (2001). Inactivation determinants in segment IIIS6 of Ca(v)3.1. J. Physiol., 537, 27-34.
18. MARTlNEZ, M.L., HEREDIA, M.P. & DELGADO, C. (1999). Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J. Mol. Cell Cardiol., 31, 1617-1625.
19. MASON, R.P. (1993). Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity. Biochemi. Pharmacol., 45, 2173-2183.
20. MASUDA, Y. & TANAKA, S. (1994). Efonidipine hydrochloride: a new calcium antagonist. Cardivasc. Drug Rev., 12, 123-135.
21. MASUMIYA, H., SHIJUKU, T., TANAKA, H. & SHIGENOBU, K. (1998). Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur. J. Pharmacol., 349, 351-357.
22. 2+ channel antagonists on sinus node: prolongation of late phase 4 depolarization by efonidipine. Eur. J. Pharmacol., 335, 15-21.
23. MIKAMI, A., IMOTO, K., TANABE, T., NIIDOME, T., MORI, Y., TAKESHIMA, H., NARUMIYA, S. & NUMA, S. (1989). Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature, 340, 230-233.
24. 2+ channels by Ro 40-5967. Circ. Res., 75, 144-148.
25. MONTEIL, A., CHEMIN, J., BOURINET, E., MENNESSIER, G., LORY, P. & NARGEOT, J. (2000). Molecular and functional properties of the human alpha(1G) subunit that forms T-type calcium channels. J. Biol. Chem., 275, 6090-6100.
26. MORI, Y., FRIEDRICH, T., KIM, M.-S., MIKAMI, A., NAKAI, J., RUTH, P., BOSSE, E., HOFMANN, F., FLOCKERZI, V., FURUICHI, T., MIKOSHIBA, K., IMOTO, K., TANABE, T. & NUMA, S. (1991). Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature, 350, 398-402.
27. NAKAMURA, K., NUKADA, T., HAGA, T. & SUGIYAMA, H. (1994). G protein-mediated inhibition of phosphoinositide metabolism evoked by metabotropic glutamate receptors in frog oocytes. J. Physiol., 414, 35-41.
28. NIIDOME, T., KIM, M.S., FRIEDRICH, T. & MORI, Y. (1992). Molecular cloning and characterization of a novel calcium channel from rabbit brain. FEBS Lett., 308, 7-13.
29. ONO, K., LEE, T.-S., KAKU, T. & ARITA, M. (2000). Pharmacological properties of the human cardiac cloned T-type calcium channel. Jpn. J. Electrocardiol., 20, 109-112.
30. PEREZ-REYES, E. (2003a). Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev., 83, 117-161.
31. PEREZ-REYES, E. (2003b). Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev., 83, 117-161.
32. PEREZ-REYES, E., CRIBBS, L.L., DAUD, A., LACERDA, A.E., BARCLAY, J., WILLIAMSON, M.P., FOX, M., REES, M. & LEE, J.H. (1998). Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature, 391, 896-900.
33. SAKODA, R., MATSUMOTO, H. & SETO, K. (1992). Synthesis and crystal structure of optically active 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2- oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3- pyridinecarboxylate (NZ-105). Chem. Pharm. Bull. (Tokyo), 40, 2377-2381.
34. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ. Res., 75, 149-155.
35. 2+ channels. Trends Pharmacol. Sci., 19, 108-115.
36. TALAVERA, A. & BASILICO, C. (1977). Temperature sensitive mutants of BHK cells affected in cell cycle progression. J. Cell. Physiol., 92, 425-436.
37. TANAKA, H. & SHIGENOBU, K. (2002). Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc. Drug Rev., 20, 81-92.
38. TRIGGLE, D.J. & RAMPE, D. (1989). 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions. Trends Pharmacol. Sci., 10, 507-511.
39. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br. J. Pharmacol., 122, 37-42.
40. VAN DER VRING, J.A., CLEOPHAS, T.J., VAN DER WALL, E.E. & NIEMEYER, M.G. (1999). T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. Am. J. Ther., 6, 229-233.
41. + channels by G-protein bg-subunits. EMBO J., 19, 4915-4925.
42. WAKAMORI, M., YAMAZAKI, K., MATSUNODAIRA, H., TERAMOTO, T., TANAKA, L, NIIDOME, T., SAWADA, K., NISHIZAWA, Y., SEKIGUCHI, N., MORI, E., MORI, Y. & IMOTO, K. (1998). Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel. J. Biol. Chem., 273, 34857-34867.